Edesa Biotech, Inc. (EDSA)

Market Cap	13.97M
Revenue (ttm)	n/a
Net Income (ttm)	-5.84M
Shares Out	7.02M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,879
Open	1.960
Previous Close	1.952
Day's Range	1.960 - 2.050
52-Week Range	1.550 - 5.590
Beta	0.38
Analysts	Strong Buy
Price Target	13.00 (+553.66%)
Earnings Date	Aug 8, 2025

About EDSA

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic conta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 16
• Stock Exchange: NASDAQ
• Ticker Symbol: EDSA
• Website: https://www.edesabiotech.com

Analyst Forecast

According to 2 analysts, the average rating for EDSA stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 553.66% from the latest price.

Price Target

$13.0

(553.66% upside)

Analyst Consensus: Strong Buy